A non-human primate model with Alzheimer’s disease-like pathology induced by hippocampal overexpression of human tau

share:

Brief intro:

  • Author: Zhouquan Jiang, Jing Wang, Bin Luo, Fan Bai, Yongpeng Qin, Huiyi Wei, Shaojuan Zhang, Junjie Wei, Guoyu Ding, Long Ma, Shu He, Rongjie Chen, Lu Wang, Hao Xu, Xiangyu Wang, Gong Chen, Wenliang Lei
  • Journal: BioRxiv
  • Doi: https://www.doi.org/10.1101/2022.10.26.513832
  • Publication Date: 2022 Oct 30

Products/Services used in the paper

Quotation shows PackGene:And all the AAVs we have used in this study were produced by PackGene Biotech Inc. (Guangzhou, China).

Research Field:CNS

Targeted organ:brain

Animal or cell line strain:monkey

Request Quote

Abstract

Alzheimer’s disease (AD) is one of the most burdening diseases of the century with no disease-modifying treatment yet. Non-human primates (NHPs) share genetic, anatomical and physiological similarities with humans, making them an ideal model for investigating the pathogenesis and therapeutics of AD. However, the applications of NHPs in AD research have been hindered by the paucity of spontaneous or induced monkey models for AD due to their long generation time, ethical considerations and technical challenges in making genetically modified monkeys. Here we developed an AD-like NHP model by overexpressing human tau in bilateral hippocampi of adult rhesus macaque monkeys. We evaluated the pathological features of these monkeys with immunostaining, cerebrospinal fluid (CSF) analysis, magnetic resonance imaging (MRI), positron emission tomography (PET) scan, and behavioral tests. We demonstrated that after hippocampal overexpression of human tau, the rhesus macaque monkeys displayed multiple pathological features of AD, including neurofibrillary tangle formation, neuronal loss, hippocampal atrophy, neuroinflammation, Aβ clearance deficit, blood vessel damage and cognitive decline. This work establishes a human tau-induced AD-like NHP model that may facilitate mechanistic studies and therapeutic treatments for AD.

About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Download